Presently, there are two approved drug and over 150 product candidates, which are being evaluated
Significant advancements in the developmentalpipeline across various oncological disorders, infectious diseases and geneticdisorders have amplified the interest of various pharmaceutical establishmentsand have inspired research groups across the world, to focus their efforts onthe development of RNAi therapeutics. Further, there are multiple pipelinecandidates in mid to late-stage (phase II and above) trials and are anticipatedto enter the market over the next 5-10 years.
To order this 350+ page report, which features 130+ figuresand 190+ tables, please visit this https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
The USD 9.2 billion (by 2030) financialopportunity within the RNAi therapeutics market has been analyzed across thefollowing segments:
§ Key therapeutic areas
§ Oncological disorders
§ Infectious diseases
§ Genetic disorders
§ Ophthalmic disorders
§ Hepatic disorders
§ Respiratory disorders
§ Type of RNAi molecule
§ siRNA
§ miRNA
§ shRNA
§ sshRNA
§ DNA
§ Route ofadministration
§ Subcutaneous
§ Intravenous
§ Intradermal
§ Intratumoral
§ Intravitreal
§ Oral
§ Intramuscular
§ Key geographicalregions
§ North America
§ Europe
§ Asia Pacific and theRest of the World
§ Leading Players
The RNAiTherapeutics Market (2ndEdition), 2019-2030 report features the following companies, which weidentified to be key players in this domain:
§ Quark Pharmaceuticals
§ Alnylam Pharmaceuticals
§ Dicerna Pharmaceuticals
§ Souzhou Ribo Life Sciences
§ Olix Pharmaceuticals
§ Sirnaomics
§ Ariz Precision Medicine
§ Arrowhead Pharmaceuticals
§ Gradalis
§ Benitec Biopharma
Table of Contents
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. COMPETITIVE LANDSCAPE
5. COMPANY COMPETITIVENESSANALYSIS
6. LATE STAGE RNAi THERAPEUTICS
7. TECHNOLOGY PLATFORMS AND DELIVERY SYSTEMS
8. KEY THERAPEUTIC INDICATIONS
9. CLINICAL TRIAL ANALYSIS
10. PATENT ANALYSIS
11. RECENT PARTNERSHIPS
12. FUNDING AND INVESTMENT ANALYSIS
13. PROMOTIONAL ANALYSIS
14. MARKET SIZING ANDOPPORTUNITY ANALYSIS
15. RNAi IN DIAGNOSTICS
16. SERVICE PROVIDERSFOR RNAi THERAPEUTICS
17. SWOT ANALYSIS
18. CONCLUSION
19. INTERVIEW TRANSCRIPT(S)
20. APPENDIX 1:TABULATED DATA
21. APPENDIX 2: LISTOF COMPANIES AND ORGANIZATIONS
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
